Cipla: Margins under pressure - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Cipla: Margins under pressure

Aug 4, 2003

Domestic pharma major, Cipla announced its first quarter FY04 results recently. While the company has posted a 13% increase in the topline, a marginal drop in the operating efficiency has restricted the company's bottomline growth at 11%. Let us briefly evaluate the performance of the company during 1QFY04.

(Rs m) 1QFY03 1QFY04 Change
Net Sales 4,030 4,542 12.7%
Other Income 48 67 39.7%
Total expenditure 3,207 3,669 14.4%
Operating Profit (EBDIT) 823 874 6.2%
Operating Profit Margin (%) 20.4% 19.2%  
Interest 2 10 330.4%
Depreciation 70 88 25.0%
Profit before Tax 798 843 5.6%
Tax 192 171 -10.9%
Profit after Tax/(Loss) 606 672 10.8%
Net profit margin (%) 15.0% 14.8%  
No. of Shares (m) 60.0 60.0  
Earnings per share* 40.4 44.8  
Current P/e ratio   18.0  

Cipla recorded a healthy growth in the net sales. However, a 25% rise in the raw material expense has affected the margins of the company. Raw material cost as a percentage of sales has gone up from 44% in 1QFY03 to 49% in the current quarter. This was primarily due to the change in the product mix of the company. Depreciation charges were also on the higher side on account of provision being made for the second phase of the Goa unit, which commenced commercial production during the quarter under review. Other income increased due to higher export benefits received during the current quarter. A drop in operating profit margins, sharp rise in the interest cost and a drop in the tax provisions on account of Sec 80I benefits have resulted in Cipla registering an 11% rise in net profits. Let us now study the revenue break up of the company.

Revenue break-up
(Rs m) 1QFY03 1QFY04 Change
Domestic 2,624 3,054 16.4%
Formulations 507 884 74.3%
Bulk drugs 882 562 -36.3%
Other operating income 16 42 161.1%
Total 4,030 4,542 12.7%

A close examination of the revenues indicates that although the export of formulations saw a steep rise, bulk drugs exports registered a sharp decline. This was on account of postponement of purchases by customers due to delay in patent rulings. On the domestic front, Cipla managed to outperform the industry with strong performance in the anti-biotic, anti-asthmatics and anti-hypertensives segments. The company has launched ‘Tiotropium’, a dry powder inhaler in the anti-asthma segment during the current quarter. Exports of formulations have seen a 74% growth. The growth was fuelled by good performance in the anti-AIDS segment.

Cipla has indicated that the export of CFC - free inhalers to Europe will commence as soon as the required regulatory approvals are received. However, the company has refused to give a time frame within which it expects to receive the requisite approval.

At Rs 807, Cipla is trading at a P/E of 18x its 1QFY04 earnings. Given the company’s ability to outperform in the domestic markets and the likely approval for export of CFC - free inhalers, the prospects of the company seem bright. However, delay in regulatory approval for products for which Cipla is the bulk drugs supplier and the uncertainty in respect of DPCO remain a cause for concern.

Equitymaster requests your view! Post a comment on "Cipla: Margins under pressure". Click here!


More Views on News

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 23, 2020 02:57 PM